Logo image of IMNN

IMUNON INC (IMNN) Stock Fundamental Analysis

NASDAQ:IMNN - Nasdaq - US15117N6022 - Common Stock - Currency: USD

0.84  0 (0%)

After market: 0.84 0 (0%)

Fundamental Rating

2

Taking everything into account, IMNN scores 2 out of 10 in our fundamental rating. IMNN was compared to 566 industry peers in the Biotechnology industry. The financial health of IMNN is average, but there are quite some concerns on its profitability. IMNN has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year IMNN has reported negative net income.
In the past year IMNN has reported a negative cash flow from operations.
IMNN had negative earnings in each of the past 5 years.
In the past 5 years IMNN always reported negative operating cash flow.
IMNN Yearly Net Income VS EBIT VS OCF VS FCFIMNN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

IMNN's Return On Assets of -186.58% is on the low side compared to the rest of the industry. IMNN is outperformed by 88.34% of its industry peers.
IMNN has a worse Return On Equity (-483.33%) than 78.45% of its industry peers.
Industry RankSector Rank
ROA -186.58%
ROE -483.33%
ROIC N/A
ROA(3y)-66.24%
ROA(5y)-59.99%
ROE(3y)-101.8%
ROE(5y)-107.31%
ROIC(3y)N/A
ROIC(5y)N/A
IMNN Yearly ROA, ROE, ROICIMNN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

IMNN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IMNN Yearly Profit, Operating, Gross MarginsIMNN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -2K -4K -6K

More info and screens

5

2. Health

2.1 Basic Checks

IMNN does not have a ROIC to compare to the WACC, probably because it is not profitable.
IMNN has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, IMNN has more shares outstanding
IMNN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IMNN Yearly Shares OutstandingIMNN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M
IMNN Yearly Total Debt VS Total AssetsIMNN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of -62.70, we must say that IMNN is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of IMNN (-62.70) is worse than 94.35% of its industry peers.
There is no outstanding debt for IMNN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -62.7
ROIC/WACCN/A
WACC29.17%
IMNN Yearly LT Debt VS Equity VS FCFIMNN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

IMNN has a Current Ratio of 1.51. This is a normal value and indicates that IMNN is financially healthy and should not expect problems in meeting its short term obligations.
IMNN has a Current ratio of 1.51. This is amonst the worse of the industry: IMNN underperforms 82.16% of its industry peers.
IMNN has a Quick Ratio of 1.51. This is a normal value and indicates that IMNN is financially healthy and should not expect problems in meeting its short term obligations.
IMNN's Quick ratio of 1.51 is on the low side compared to the rest of the industry. IMNN is outperformed by 81.27% of its industry peers.
Industry RankSector Rank
Current Ratio 1.51
Quick Ratio 1.51
IMNN Yearly Current Assets VS Current LiabilitesIMNN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 21.10% over the past year.
EPS 1Y (TTM)21.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.69%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

IMNN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.91% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y30.97%
EPS Next 2Y20.8%
EPS Next 3Y17.23%
EPS Next 5Y17.91%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IMNN Yearly Revenue VS EstimatesIMNN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
IMNN Yearly EPS VS EstimatesIMNN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -100 -200 -300

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

IMNN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year IMNN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMNN Price Earnings VS Forward Price EarningsIMNN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IMNN Per share dataIMNN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as IMNN's earnings are expected to grow with 17.23% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.8%
EPS Next 3Y17.23%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IMNN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IMUNON INC

NASDAQ:IMNN (5/1/2025, 6:38:59 PM)

After market: 0.84 0 (0%)

0.84

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-27 2025-02-27/bmo
Earnings (Next)05-19 2025-05-19
Inst Owners2.93%
Inst Owner Change-0.06%
Ins Owners1.14%
Ins Owner Change0%
Market Cap12.28M
Analysts82
Price Target13.87 (1551.19%)
Short Float %7.08%
Short Ratio7.84
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.01%
Min EPS beat(2)7.97%
Max EPS beat(2)10.04%
EPS beat(4)3
Avg EPS beat(4)9.68%
Min EPS beat(4)-24.34%
Max EPS beat(4)45.04%
EPS beat(8)4
Avg EPS beat(8)-4.7%
EPS beat(12)6
Avg EPS beat(12)-30.14%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.03%
PT rev (3m)3.03%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.28
P/tB 3.28
EV/EBITDA N/A
EPS(TTM)-1.72
EYN/A
EPS(NY)-1.19
Fwd EYN/A
FCF(TTM)-1.29
FCFYN/A
OCF(TTM)-1.27
OCFYN/A
SpS0
BVpS0.26
TBVpS0.26
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -186.58%
ROE -483.33%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-66.24%
ROA(5y)-59.99%
ROE(3y)-101.8%
ROE(5y)-107.31%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 3729.41%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.51
Quick Ratio 1.51
Altman-Z -62.7
F-Score1
WACC29.17%
ROIC/WACCN/A
Cap/Depr(3y)87.77%
Cap/Depr(5y)62.92%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.69%
EPS Next Y30.97%
EPS Next 2Y20.8%
EPS Next 3Y17.23%
EPS Next 5Y17.91%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y17.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y16.15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y16.35%
OCF growth 3YN/A
OCF growth 5YN/A